The trial follows a similar one with Type 2 diabetic patients.
Biopharmaceutical company Oramed Pharmaceuticals Inc. (Bulletin Board:ORMP); DAX:OJU) has launched a Phase IIa safety and efficacy trial of ORMD 0801, its oral insulin capsule, on Type 1 diabetics at the Hadassah University Medical Center.
The latest trial follows a similar trial on Type 2 diabetic patients, which demonstrated that ORMD 0801 had a good safety profile and was effective in lowering blood glucose levels without any serious adverse events.
Oramed CEO Nadav Kidron said, "The commencement of trials of our oral insulin capsule on Type 1 diabetics signals another major step forward for our company in the treatment of diabetes. The successful results from our trials on Type 2 diabetics were very encouraging and we hope to achieve similar results from our Type 1 trials as well.”
Oramed's share closed at $0.63 on Nasdaq yesterday.
Published by Globes [online], Israel business news - www.globes-online.com - on September 24, 2008
© Copyright of Globes Publisher Itonut (1983) Ltd. 2008